ROPINIROLE tablet, film coated

Country: Amerika Syarikat

Bahasa: Inggeris

Sumber: NLM (National Library of Medicine)

Bahan aktif:

ROPINIROLE HYDROCHLORIDE (UNII: D7ZD41RZI9) (ROPINIROLE - UNII:030PYR8953)

Boleh didapati daripada:

Marlex Pharmaceuticals Inc

Laluan pentadbiran:

ORAL

Jenis preskripsi:

PRESCRIPTION DRUG

Tanda-tanda terapeutik:

Ropinirole tablets are indicated for the treatment of Parkinson’s disease. Ropinirole tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Ropinirole hydrochloride is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. Risk Summary There are no adequate data on the developmental risk associated with the use of ropinirole hydrochloride in pregnant women. In animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (MRHD) for Parkinson’s disease. Ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. In pregnant rabbits, ropinirole potentiated the teratogenic effects of L-dopa when these drugs

Ringkasan produk:

Ropinirole Tablet, USP 0.25 mg are white pentagonal tablets engraved “ROP” over “.25” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0673-01 Ropinirole Tablet, USP 0.5 mg are yellow pentagonal tablets engraved “ROP” over “.5” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0674-01 Ropinirole Tablet, USP 1 mg are green pentagonal tablets engraved “ROP” over “1” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0675-01 Ropinirole Tablet, USP 2 mg are pink pentagonal tablets engraved “ROP” over “2” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0676-01 Ropinirole Tablet, USP 3 mg are purple pentagonal tablets engraved “ROP” over “3” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0677-01 Ropinirole Tablet, USP 4 mg are pale brown pentagonal tablets engraved “ROP” over “4” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0678-01 Ropinirole Tablet, USP 5 mg are blue pentagonal tablets engraved “ROP” over “5” on one side, “MLX” on the other side. They are supplied as follows: Bottles of 100s: NDC 10135-0679-01 STORAGE Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Close container tightly after each use.

Status kebenaran:

Abbreviated New Drug Application

Ciri produk

ROPINIROLE- ROPINIROLE TABLET, FILM COATED
MARLEX PHARMACEUTICALS INC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO
USEROPINIROLE TABLETS
SAFELY AND EFFECTIVELY.SEE FULL PRESCRIBING INFORMATION FORROPINIROLE
TABLETS.
ROPINIROLE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1997
RECENT MAJOR CHANGES
Warnings and Precautions,
Withdrawal Symptoms ( 5.8) 9/2021
Melanoma-removal ( 5.9) 9/2021
INDICATIONS AND USAGE
Ropinirole tablet is a non-ergoline dopamine agonist indicated for the
treatment of Parkinson’s disease
(PD) and moderate- to-severe primary Restless Legs Syndrome (RLS). (
1.1, 1.2)
DOSAGE AND ADMINISTRATION
Ropinirole hydrochloride tablets can be taken with or without food. (
2.1)
Retitration of ropinirole hydrochloride may be warranted if therapy is
interrupted. ( 2.1)
_PARKINSON’S DISEASE:_
The recommended starting dose is 0.25 mg taken three times daily;
titrate to a maximum daily dose of
24 mg. ( 2.2)
Renal Impairment: The maximum recommended dose is 18 mg/day in
patients with end-stage renal
disease on hemodialysis. ( 2.2)
_RESTLESS LEGS SYNDROME:_
The recommended starting dose is 0.25 mg once daily, 1 to 3 hours
before bedtime, titrate to a
maximum recommended dose of 4 mg daily. ( 2.3)
Renal Impairment: The maximum recommended dose is 3 mg/day in patients
with end-stage renal
disease on hemodialysis. ( 2.3)
DOSAGE FORMS AND STRENGTHS
Tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg ( 3)
CONTRAINDICATIONS
History of hypersensitivity/allergic reaction (including urticaria,
angioedema, rash, pruritus) to ropinirole or
to any of the excipients. ( 4)
WARNINGS AND PRECAUTIONS
Sudden onset of sleep and somnolence may occur ( 5.1)
Syncope may occur ( 5.2)
Hypote nsion, including orthostatic hypotension may occur ( 5.3)
May cause hallucinations and psychotic-like behaviors ( 5.4)
May cause or exacerbate dyskinesia ( 5.5)
May cause problems with impulse control or compulsive behaviors ( 5.6)
ADVERSE REACTIONS
Most common adverse rea